Purchase this article with an account.
Sandro Di Simplicio, Jeff Hogg; A retrospective comparison of aflibercept and ranibizumab in the management of macular oedema secondary to retinal vein occlusion. Invest. Ophthalmol. Vis. Sci. 2018;59(9):4259. doi: https://doi.org/.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To illustrate any visual or anatomical benefit that may be derived from preferentially selecting aflibercept or ranibizumab IVI for the treatment of macular oedema in RVO
Electronic medical records at the Newcastle Eye Centre were retrospectively searched for cases receiving more than 2 aflibercept or ranibizumab IVIs for macular oedema secondary to RVO between January 2014 and September 2017
710 consecutive eyes (697 patients) met search criteria; 387 branch RVO and 323 central RVO. Mean follow-up was 24 months with a mean of 9.7 injections per eye. Eyes receiving only aflibercept gained a mean 11.1 ETDRS letters (95% confidence interval 8.8-13.3) with 49% (43%-55%) achieving a dry macula compared to the means of 5.3 letters (3.0-7.6) (p=0.003) and 38% dryness (31-45%) (p=0.016) in eyes receiving only ranibizumab. Eyes receiving only aflibercept had a mean of 6.1 (5.6-6.5) injections compared to 7.5 (6.9-8.1) injections for eyes receiving only ranibizumab (p=0.0004). Eyes switched from a mean of 9.4 (8.6-10.2) ranibizumab IVIs to aflibercept gained a mean of 3.8 letters (1.0-6.6) and 26% (20-31%) achieved a dry macula following therapeutic switch
These pragmatic data suggest that aflibercept offers superior visual and anatomical outcomes to ranibizumab for patients with macular oedema secondary to retinal vein occlusion
This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.
This PDF is available to Subscribers Only